CVRx Shuffles Sales Leadership Amid Commercial Execution Challenges
Event summary
- Robert John, Chief Revenue Officer of CVRx, departs effective August 11, 2026.
- Paul Verrastro assumes interim role as Head of Sales, bringing over 30 years of medical device sales experience.
- Verrastro previously held roles at Guidant, Boston Scientific, and Medtronic, focusing on novel cardiovascular therapies.
The big picture
CVRx’s leadership transition underscores broader challenges in commercial execution within the medical device sector. The shift comes as the company seeks to solidify its position in neuromodulation solutions for cardiovascular diseases, competing against established players like Medtronic and Boston Scientific. The interim appointment of Verrastro highlights the importance of leveraging deep industry experience to navigate regulatory and market dynamics.
What we're watching
- Leadership Stability
- Whether CVRx can maintain sales momentum during the leadership transition.
- Commercial Strategy
- How Verrastro’s experience will impact CVRx’s commercial execution and market positioning.
- Permanent Succession
- The timeline for appointing a permanent successor and their strategic fit with CVRx’s goals.
Related topics